and < 80% compliance with placebo during the baseline phase. Intervention: Atorvastatin, 10 mg daily (n = 1429), or placebo (n = 1412). Outcomes: A composite endpoint consisting of an acute coronary heart disease event (myocardial infarction including silent infarction, unstable angina, acute coronary heart disease death, or resuscitated cardiac arrest), coronary revascularization procedures, or stroke. Patient follow-up: 99% (intention-to-treat analysis).
M a i n r e s u l t s
The rates for the composite endpoint were lower in the atorvastatin group than in the placebo group (Table) . When individual components of the composite endpoint were evaluated, the atorvastatin group had lower rates for acute coronary events and stoke, but not for coronary revascularization (Table) .
C o n c l u s i o n
In patients with type 2 diabetes mellitus, atorvastatin was more effective than placebo for reducing the rate of major cardiovascular disease events. 
C o m m e n t a r y
Before the trial by Colhoun and colleagues, evidence for lipid lowering for primary prevention of CVD in patients with diabetes came only from the Heart Protection Study (HPS) (1) and subgroup analyses from trials in which treatment allocation was not stratified by diabetes status (2, 3) . In CARDS, patients with type 2 diabetes and 1 other risk factor for coronary artery disease or retinopathy had a 35% relative risk reduction in CVD attributed to atorvastatin, 10 mg daily, similar to a 33% relative risk reduction in CVD with simvastatin, 40 mg daily in the HPS (1). Participants' baseline mean low-density lipoprotein (LDL) level (3.0 mmol/L [117 mg/dL]) was unchanged in the placebo group but decreased by 31% in the atorvastatin group after 4 years. Prevention of CVD attributed to atorvastatin was of a similar magnitude regardless of participants' baseline lipid levels, which suggests that a threshold level below which statin therapy should be withheld does not exist.
These data show that substantial CVD risk reductions can be realized by achieving relative reductions in LDL levels with 1 drug at a fixed dose, but neither the CARDS nor the HPS addressed the risk or benefit for further LDL reduction with increasing doses of drugs or combinations of drugs to target "goal" lipid levels.
In CARDS and HPS, adverse events, including rhabdomyolysis, did not increase with statin therapy. Although participants in randomized controlled trials may not represent all patients seen in clinical practice, participants in CARDS had comorbid conditions similar to most patients with diabetes. The CARDS and HPS provide conservative estimates of 25% to 27% 10-year risk for CVD in untreated patients with diabetes and direct evidence of the substantial benefit and low risk of statin therapy for primary prevention of CVD.
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